Efgartigimod is an FcRn inhibitor that was developed by Argenx to tackle the symptoms of myasthenia gravis (MG). It has been studied in a phase 3 and extended trial (ADAPT and ADAPT+) and has been made available through the Early Access to Medicines Scheme (EAMS).

Myaware's guide

So far, efgartigimod has been assessed in two committee meetings with NICE to decide whether it can be positively recommended for use on the NHS. Currently, it is receiving negative guidance while some concerns remain regarding a few key items. These key items include IVIg use and carer impact.

We welcome the public to comment on this guidance and you can do so using the NICE website page for the efgartigimod appraisal.

To assist those who may not have commented publicly before, we have prepared a short guide on how to comment, and pointed towards areas we feel the patient voice will be most important. We’d like to emphasise this guide is not to be used to shape your opinion, but instead make the experience a little easier.

Read more about Efgartigimod